Mylan launches generic model of Remdesivir in India for COVID-19 sufferers


New Delhi, July 20

Pharma main Mylan on Monday mentioned it has commercially launched the generic model of Remdesivir drug underneath the model identify ‘Desrem’ in India for therapy of coronavirus sufferers.

The firm had earlier mentioned that its Remdesivir might be accessible in July in India at a value of Rs 4,800 per 100 mg vial.            

The drug is accredited for the therapy of suspected or laboratory confirmed incidences of COVID-19 in adults and kids hospitalised with extreme displays of the illness, Mylan mentioned in a press release.     

The firm has launched the primary batch of its generic Remdesivir and can proceed to extend its provide throughout the nation within the wake of the rising demand for the drug, it added.            

The firm has additionally launched a helpline quantity for accessing details about the supply of Desrem in India, the assertion mentioned.

Mylan will manufacture Desrem in its injectable facility in Bengaluru, which is able to work to service the demand in India and different export markets the place Mylan has acquired a licence from Gilead for the commercialisation of Remdesivir, it added.

“With the launch of Desrem and our national 24/7 COVID-19 helpline, we aim to enhance access to this critical medicine, used for treating adults and children with severe presentations of COVID-19,” Mylan, India and Emerging  Markets, President Rakesh Bamzai mentioned.

In the wake of accelerating instances of COVID-19 throughout India, Mylan stays dedicated to proceed its efforts within the combat towards the pandemic, he added.            

The beforehand introduced settlement between Mylan and Gilead for manufacturing and distribution of Remdesivir is a part of a long-standing historical past between the 2 organisations to deal with key public well being points starting with increasing entry to top quality, reasonably priced HIV/AIDS antiretrovirals, Mylan mentioned.

In May, Mylan and home pharma companies Hetero, Cipla and Jubilant Life Sciences had entered into non-exclusive licensing agreements with drug main Gilead Sciences Inc for manufacturing and distribution of Remdesivir.

Hetero and Cipla have already launched their generic variations of Remdesivir in India.

The drugs has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (USFDA) to deal with COVID-19 sufferers. —PTI

 



Be the first to comment on "Mylan launches generic model of Remdesivir in India for COVID-19 sufferers"

Leave a comment

Your email address will not be published.


*


%d bloggers like this: